Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2008
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 57 citations in OpenAlex.
- Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.Journal of the International AIDS Society · 2014Trial
- Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.Clinical pharmacology and therapeutics · 2012Trial
- Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients.AIDS (London, England) · 2009Trial
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV.Cardiovascular drugs and therapy · 2022Review
- HIV infection and coronary heart disease: mechanisms and management.Nature reviews. Cardiology · 2019Review
- Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.Expert opinion on pharmacotherapy · 2019Review
- Dysregulation of Neuronal Cholesterol Homeostasis upon Exposure to HIV-1 Tat and Cocaine Revealed by RNA-Sequencing.Scientific reports · 2018Article
- Novel activities of safe-in-human broad-spectrum antiviral agents.Antiviral research · 2018Review
- Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases · 2017Review
- Ezetimibe: an update on its clinical usefulness in specific patient groups.Therapeutic advances in chronic disease · 2017Review
- Novel functions of PXR in cardiometabolic disease.Biochimica et biophysica acta · 2016Review
- Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.World journal of virology · 2015Review
- Epidemiology and management of antiretroviral-associated cardiovascular disease.The open AIDS journal · 2015Article
- Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.HIV/AIDS (Auckland, N.Z.) · 2015Review
- Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial.BMC infectious diseases · 2014Article
- Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.Reviews in endocrine & metabolic disorders · 2013Review
- Management of dyslipidemia in HIV-infected patients.Clinical lipidology · 2011Article
- Dyslipidemia and lipid management in HIV-infected patients.Current opinion in endocrinology, diabetes, and obesity · 2011Review
- Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.Current atherosclerosis reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.